Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

Jazz Pharmaceuticals has announced a definitive agreement to acquire Chimerix, a US-based biotech firm, for approximately ...

Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have entered into a definitive agreement for Jazz to acquire ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...

A drugmaker developing a brain tumor treatment is being acquired in a $935 million deal.

At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 ...

Stifel reiterated a Buy rating and $230 price target on Jazz Pharmaceuticals (JAZZ) after the company agreed to acquire Chimerix (CMRX). The ...

Jazz Pharmaceuticals said Wednesday it would spend nearly $1 billion to buy Chimerix and its experimental pill for a ...

Chimerix shares surged to a multi-year high Wednesday after the biopharmaceutical company agreed to be acquired by larger peer Jazz Pharmaceuticals for about $935 million. Jazz is paying $8.55 a share ...

The decision to acquire Chimerix comes just a few months after Jazz claimed FDA approval for Ziihera (zanidatamab), its ...